Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker.
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is being used in oncology as a noninvasive method for measuring properties of the tumor microvasculature. There is potential for DCE-MRI to be used as an imaging biomarker to measure antiangiogenic effects of cancer treatments. This article reviews the general methodology for performing DCE-MRI and discusses existing data and challenges to applying DCE-MRI for treatment response assessment in clinical trials.
Hylton
Nola
N
University of California, San Francisco, San Francisco, CA 94143-1290, USA. nola.hylton@radiology.ucsf.edu
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D017321:Clinical Trials, Phase I as Topic; D003287:Contrast Media / Q000008:administration & dosage*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D009369:Neoplasms / Q000175:diagnosis*; D011379:Prognosis; D011446:Prospective Studies
D020533:Angiogenesis Inhibitors; D014408:Biomarkers, Tumor; D003287:Contrast Media